Figure 1.

Visual representation of the possible outcomes, including imaging radiation-induced malignancy in a population of early breast cancer patients (age 50–59 years) participating in an adjuvant clinical trial (outcome at 28 years) (A) and a population of advanced breast cancer patients (age 50–59 years) participating in a metastatic clinical trial (outcome at 5 years) (B). Based on data from Schairer et al. [49]. In adjuvant trials, the risk depends on the imaging protocol requirements (see text). In metastatic trials, no cases of imaging radiation-induced tumors are expected.

Abbreviation: IRIM, imaging radiation-induced malignancy.